Abante Renta FI (0P000019IN)

Overview

The investment objective of this Sub-fund is centered around capital preservation and the achievement of long-term capital growth. This is to be accomplished by strategically investing within the biotechnology sector, focusing particularly on the generic pharmaceuticals, large pharmaceuticals, and specialty pharmaceuticals sub-sectors. The Sub-fund aims to diversify its investments across various geographies and market capitalisations, with a special focus on North America and the NASDAQ market, particularly targeting small and mid-capitalized companies. This investment approach is designed to leverage the dynamic and evolving opportunities within the biotechnology and pharmaceutical sectors, catering to investors looking for growth in a highly specialized field.

Products and Services

• Investment in Biotechnology Sector: The Sub-fund primarily invests in the biotechnology sector, tapping into the potential of companies engaged in the research, development, and commercialization of innovative medical treatments, therapies, and technologies. This includes investments in biotech firms working on cutting-edge solutions for diverse medical challenges.

• Generic Pharmaceuticals: A significant portion of the Sub-fund's investments is directed towards companies within the generic pharmaceuticals sub-sector. These firms are involved in the manufacture and sale of medication that is equivalent to brand-name products in dosage form, strength, route of administration, quality, performance characteristics, and intended use, but are typically sold at lower prices.

• Large Pharmaceuticals: The Sub-fund also invests in large, well-established pharmaceutical companies. These entities are characterized by their extensive product lines, significant research and development capabilities, and global presence. Investments in this sub-sector are driven by the potential for steady growth and innovation in new drugs and treatments.

• Specialty Pharmaceuticals: Another area of focus for the Sub-fund is the specialty pharmaceuticals sub-sector, which includes companies that develop and or/markete advanced, niche products, specifically those that require special handling, administration, or monitoring. These firms often target rare or complex chronic conditions, making their offerings critical to patient care and potentially highly lucrative.

• Geographical and Market Capitalization Focus: While the Sub-fund invests globally, there is a targeted focus on North America and specifically, the NASDAQ market, given its rich ecosystem of innovative biotech and pharmaceutical companies. The Sub-fund prioritizes investments in small and mid-capitalized companies, aiming to capitalize on the growth potential of these more agile and often more innovative market players.